Skip to main content
Fig. 5 | BMC Nephrology

Fig. 5

From: UK Kidney Association Clinical Practice Guideline: Sodium-Glucose Co-transporter-2 (SGLT-2) Inhibition in Adults with Kidney Disease 2023 UPDATE

Fig. 5

Effects of SGLT-2 inhibitors on kidney disease progression by population (adapted from [4]). Kidney disease progression was defined as a sustained ≥ 50% decline in eGFR from randomisation, kidney failure, or death from kidney failure. Data not available for SOLOIST-WHF. Figure licensed under Creative Commons CC-BY license

Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us